Beta Bionics filings document a Nasdaq-listed medical device issuer commercializing diabetes-management technology for insulin-requiring people. Recent Form 8-K reports provide results of operations, financial condition, guidance-related exhibits, channel metrics for Durable Medical Equipment and Pharmacy Benefit Plan reimbursement, and disclosures tied to iLet Bionic Pancreas data and investor presentations.
The company’s proxy materials cover annual meeting matters, board-class director elections, auditor ratification, voting mechanics, and stockholder governance. Other material-event filings disclose FDA inspection correspondence involving Quality Management System, Medical Device Reporting, and Corrections and Removals, alongside the company’s registered common stock and public-company reporting status.
Beta Bionics, Inc. (BBNX) is the issuer for which T. Rowe Price Associates, Inc. reported beneficial ownership of 8,943,061 common shares, or 16.6%, as of September 30, 2026. The adviser reported sole voting power over 8,939,271 shares and sole dispositive power over 8,943,061 shares, with no shared voting or dispositive power. It expressly denied that its report should be construed as an admission that it is the beneficial owner.
T. Rowe Price Health Sciences Fund was identified as having an interest in 2,408,699 shares, or 5.4%, of the class. T. Rowe Price Associates stated that it manages the fund’s portfolio and does not serve as custodian for client assets; clients or their custodians or trustee banks have the right to receive dividends and sale proceeds.
Beta Bionics, Inc. Chief Commercial Officer Mark Hopman sold 370 shares of common stock on October 1, 2026, at a weighted average sale price of $18.96 per share under a Rule 10b5-1 plan adopted on June 10, 2026. Prices ranged from $18.96 to $19.9599 per share. After the sale, he held 56,109 shares directly.
Beta Bionics, Inc. (BBNX) officer Mark Hopman reported a planned sale of 2,660 common shares, listed with an aggregate market value of $50,486.80. Hopman states the shares are to be received through stock-option exercises over the next three months, with acquisition and payment dates corresponding to the exercise and sale dates. Morgan Stanley Smith Barney LLC is listed as broker. Four sales during the prior three months are also listed, three labeled as 10b5-1 sales.
Beta Bionics, Inc. (BBNX) director Christy Jones reported selling 6,430 shares of common stock on September 22, 2026, at $23 per share. The transaction is described as a sale in the open market or a private transaction and was made pursuant to a Rule 10b5-1 Plan adopted on February 19, 2026. Jones reported holding 19,564 shares directly after the sale.
Beta Bionics, Inc. (BBNX) director Christina Jones filed a Rule 144 notice indicating an intention to sell up to 8,942 shares of common stock of Beta Bionics through Morgan Stanley Smith Barney LLC on NASDAQ. The shares were and will be acquired upon the exercise of stock options and settlement of restricted stock units over the next three months.
Beta Bionics, Inc. (BBNX) reports that Chief Commercial Officer Mark Hopman sold 35,994 shares of common stock on September 9, 2026 at $18.4628 per share in a sale described as open market or private. The sale was made pursuant to a Rule 10b5-1 Plan adopted on June 10, 2026.
After this transaction, Hopman beneficially owned 88,033 shares of Beta Bionics common stock. This Form 4 amendment corrects an earlier filing that had incorrectly reported the number of shares disposed and the resulting beneficial ownership.
Beta Bionics, Inc. (BBNX) reported that Chief Commercial Officer Mark Hopman sold 30,779 shares of common stock on September 16, 2026. The sale was executed at a weighted average price of $20.1319 per share, in transactions ranging from $20.00 to $20.64, under a Rule 10b5-1 Plan adopted on June 10, 2026. After these sales, Hopman directly holds 56,479 shares of Beta Bionics common stock.
Beta Bionics, Inc. (BBNX) reported that Chief Product Officer Mike Mensinger sold 2,650 shares of common stock on September 16, 2026 at $22.00 per share in an open-market or private transaction. The sale was made pursuant to a Rule 10b5-1 trading plan adopted on September 8, 2025, and he continued to hold 177,390 shares of common stock directly after the transaction.
Beta Bionics, Inc. (BBNX) entered into an underwriting agreement for an underwritten public offering of 7,652,175 shares of common stock at $17.25 per share and, in lieu of common shares to certain investors, pre-funded warrants to purchase 1,043,484 shares at $17.2499 per warrant. The company expects gross proceeds of $150.0 million before underwriting discounts, commissions and expenses. The offering is expected to close on or about September 17, 2026, subject to customary closing conditions.
The underwriters have a 30-day option to purchase up to 1,304,348 additional shares at the public offering price, less underwriting discounts and commissions. Beta Bionics states it expects to use net proceeds for general corporate purposes, including commercialization of its Mint™ product, expansion of manufacturing facilities, research and clinical development, product enhancements, potential strategic opportunities, and working capital and operating expenses.
Beta Bionics, Inc. (BBNX) is conducting a primary offering of 7,652,175 shares of common stock and pre-funded warrants to purchase up to 1,043,484 shares, at $17.25 per share and $17.2499 per pre-funded warrant, for gross proceeds of $150.0 million. Net proceeds are estimated at $140.1 million, or $161.2 million if underwriters fully exercise their 30‑day option for 1,304,348 additional shares. Shares outstanding would be 52,633,781 (or 53,938,129 with the option), excluding warrant exercises. The company plans to use the cash for Mint commercialization and manufacturing expansion, R&D and clinical work, product enhancements, potential strategic opportunities, and general working capital and operating expenses.
Beta Bionics describes itself as a commercial-stage diabetes device company, with the FDA‑cleared iLet Bionic Pancreas and September 2026 FDA clearance of its Mint patch pump, plus a 510(k) submission for its 3D Intelligence insulin‑dosing algorithm. The filing also notes a pending securities class action related to statements about iLet, which the company states it intends to defend.